Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy - PubMed (original) (raw)
. 2002 Mar 15;99(6):2009-16.
doi: 10.1182/blood.v99.6.2009.
Affiliations
- PMID: 11877273
- DOI: 10.1182/blood.v99.6.2009
Free article
Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy
Claudia Rossig et al. Blood. 2002.
Free article
Abstract
Primary T cells expressing chimeric receptors specific for tumor or viral antigens have considerable therapeutic potential. Unfortunately, their clinical value is limited by their rapid loss of function and failure to expand in vivo, presumably due to the lack of costimulator molecules on tumor cells and the inherent limitations of signaling exclusively through the chimeric receptor. Epstein-Barr virus (EBV) infection of B lymphocytes is near universal in humans and stimulates high levels of EBV-specific helper and cytotoxic T cells, which persist indefinitely. Our clinical studies have shown that EBV-specific T cells generated in vitro will expand, persist, and function for more than 6 years in vivo. We now report that EBV-specific (but not primary) T cells transduced with tumor-specific chimeric receptor genes can be expanded and maintained long-term in the presence of EBV-infected B cells. They recognize EBV-infected targets through their conventional T-cell receptor and tumor targets through their chimeric receptors. They efficiently lyse both. EBV-specific T cells expressing chimeric antitumor receptors may represent a new source of effector cells that would persist and function long-term after their transfer to cancer patients.
Similar articles
- Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors.
Rossig C, Bär A, Pscherer S, Altvater B, Pule M, Rooney CM, Brenner MK, Jürgens H, Vormoor J. Rossig C, et al. J Immunother. 2006 Jan-Feb;29(1):21-31. doi: 10.1097/01.cji.0000175492.28723.d6. J Immunother. 2006. PMID: 16365597 - Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.
Savoldo B, Rooney CM, Di Stasi A, Abken H, Hombach A, Foster AE, Zhang L, Heslop HE, Brenner MK, Dotti G. Savoldo B, et al. Blood. 2007 Oct 1;110(7):2620-30. doi: 10.1182/blood-2006-11-059139. Epub 2007 May 16. Blood. 2007. PMID: 17507664 Free PMC article. - CD28 co-stimulation via tumour-specific chimaeric receptors induces an incomplete activation response in Epstein-Barr virus-specific effector memory T cells.
Altvater B, Pscherer S, Landmeier S, Niggemeier V, Juergens H, Vormoor J, Rossig C. Altvater B, et al. Clin Exp Immunol. 2006 Jun;144(3):447-57. doi: 10.1111/j.1365-2249.2006.03095.x. Clin Exp Immunol. 2006. PMID: 16734614 Free PMC article. - Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes.
Baxevanis CN, Papamichail M. Baxevanis CN, et al. Cancer Immunol Immunother. 2004 Oct;53(10):893-903. doi: 10.1007/s00262-004-0523-y. Epub 2004 May 26. Cancer Immunol Immunother. 2004. PMID: 15168086 Free PMC article. Review. - Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA, Reidy A, Mirandola L, Trotter K, Suvorava N, Figueroa A, Konala V, Aulakh A, Littlefield L, Grizzi F, Rahman RL, Jenkins MR, Musgrove B, Radhi S, D'Cunha N, D'Cunha LN, Hermonat PL, Cobos E, Chiriva-Internati M. Figueroa JA, et al. Int Rev Immunol. 2015 Mar;34(2):154-87. doi: 10.3109/08830185.2015.1018419. Int Rev Immunol. 2015. PMID: 25901860 Review.
Cited by
- GD2-targeting therapy: a comparative analysis of approaches and promising directions.
Philippova J, Shevchenko J, Sennikov S. Philippova J, et al. Front Immunol. 2024 Mar 15;15:1371345. doi: 10.3389/fimmu.2024.1371345. eCollection 2024. Front Immunol. 2024. PMID: 38558810 Free PMC article. Review. - Pathogen-specific T Cells: Targeting Old Enemies and New Invaders in Transplantation and Beyond.
Papadopoulou A, Alvanou M, Karavalakis G, Tzannou I, Yannaki E. Papadopoulou A, et al. Hemasphere. 2023 Jan 9;7(1):e809. doi: 10.1097/HS9.0000000000000809. eCollection 2023 Jan. Hemasphere. 2023. PMID: 36698615 Free PMC article. Review. - Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies.
Quach DH, Lulla P, Rooney CM. Quach DH, et al. Blood. 2023 Feb 23;141(8):877-885. doi: 10.1182/blood.2022016202. Blood. 2023. PMID: 36574622 Free PMC article. - The affinity of antigen-binding domain on the antitumor efficacy of CAR T cells: Moderate is better.
Mao R, Kong W, He Y. Mao R, et al. Front Immunol. 2022 Oct 17;13:1032403. doi: 10.3389/fimmu.2022.1032403. eCollection 2022. Front Immunol. 2022. PMID: 36325345 Free PMC article. Review. - Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors.
Yu T, Yu SK, Xiang Y, Lu KH, Sun M. Yu T, et al. Front Immunol. 2022 Jul 12;13:936496. doi: 10.3389/fimmu.2022.936496. eCollection 2022. Front Immunol. 2022. PMID: 35903099 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases